What was recalled
The U.S. Food and Drug Administration has issued a Class II recall involving a specific pharmaceutical product distributed by Lannett Company, Inc. This action centers on Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Extended-Release Capsules. Specifically, the recall targets the 5 mg strength of this medication. It is important to understand that this is not a broad withdrawal of an entire drug line, but a precise intervention focused on a single formulation where a critical manufacturing or labeling discrepancy has been identified. The product in question is designed for prescription-only use, indicated by the "Rx Only" designation on its packaging, and was marketed as an extended-release (ER) capsule. This classification is significant because it dictates how the medication is intended to function within the body over time.
The specific units affected by this recall are clearly defined by their National Drug Code (NDC) and lot numbers. The recalled product bears NDC 0527-0790-37. This code identifies the exact package configuration: a bottle containing 100 capsules of the 5 mg extended-release formulation. Within these bottles, the affected inventory is distinguished by Lot number 25285401A. Consumers and healthcare providers should verify this lot number against their current supply, as it serves as the primary identifier for whether a specific bottle is part of this recall action. The expiration date associated with this particular lot is April 2027, which helps further isolate the affected units from other batches that may have been produced concurrently but are not subject to this safety notice.
The distribution of these recalled items was nationwide across the United States, meaning they could be found in pharmacies and medical facilities in every state, including Indiana. The product was distributed by Lannett Company, Inc., located in Philadelphia, Pennsylvania, with a zip code of 19136. The recall was officially initiated on June 26, 2026. While the remedy for this recall is not yet stated in the current records, the scope of the distribution and the specific nature of the product highlight the importance of identifying these exact details. The combination of the NDC, lot number, expiration date, and manufacturer location provides a complete profile of the recalled items, allowing individuals to determine with certainty if they possess the affected medication.
The hazard, explained
To understand why this recall is serious, we first need to look at how the medication inside these capsules is supposed to work versus what is actually happening. The product in question is labeled as an Extended-Release (ER) formulation of dextroamphetamine and amphetamine salts. In pharmaceutical science, "extended-release" is a carefully engineered delivery system designed to release the drug slowly into your body over several hours. Think of it like a timed-release fuse or a slow-drip coffee maker rather than a shot of espresso. The capsule contains special pellets coated in layers that dissolve gradually, ensuring you get a steady, controlled dose throughout the day without a sharp spike in medication levels all at once.
The critical failure identified in this recall is a labeling and manufacturing mix-up. Although the outer packaging and the capsule shell are labeled to indicate that these are Extended-Release capsules, the interior actually contains only immediate-release (IR) pellets. Immediate-release medications are designed to dissolve almost immediately upon contact with stomach fluids, dumping the entire dose into your bloodstream at once. This means that instead of receiving a gentle, sustained therapeutic effect, you are effectively taking a full dose of immediate-release amphetamines in a single moment. The physical mechanism of harm here is a massive discrepancy between the intended pharmacokinetic profile (how the drug moves through the body) and the actual chemical release.
This sudden surge of medication can lead to significant health risks, particularly for individuals whose bodies are sensitive to rapid changes in stimulant levels. When amphetamines hit the system all at once, it can cause a sharp increase in heart rate and blood pressure. For people with underlying heart conditions, this acute stress on the cardiovascular system can be dangerous. It may also lead to symptoms of overdose or toxicity that would not occur with the properly formulated ER product, such as severe anxiety, agitation, tremors, or difficulty sleeping. Because the drug is released too quickly, the body cannot regulate the intake effectively, potentially leading to a "crash" later in the day when the medication wears off too abruptly.
While the FDA has not reported specific incidents of injury for this particular lot as of the recall date, the potential for harm is real because the dosage intensity is fundamentally altered. The hazard is not that the drug itself is poisonous, but that its delivery mechanism is wrong. Taking a full day’s worth of immediate-release medication in one sitting can overwhelm your system, leading to adverse effects that are both uncomfortable and potentially medically significant. This is why identifying and stopping use immediately is crucial for maintaining safety.
Who is most at risk
When a medication meant to provide a steady, controlled release of active ingredients suddenly delivers its entire dose all at once, the people who depend on that consistency are the ones facing the greatest danger. In this specific recall involving Lannett Company Inc.’s Dextroamphetamine Saccharate and Amphetamine-based Extended-Release Capsules, the primary group at risk is anyone currently taking these 5 mg capsules for conditions such as Attention Deficit Hyperactivity Disorder (ADHD) or narcolepsy. These medications are not over-the-counter supplements; they are prescription-only drugs that require careful management. The individuals most vulnerable to this labeling mix-up are those who rely on the pharmacokinetic profile of extended-release formulations to maintain focus and stability throughout their day without experiencing sudden spikes in drug concentration.
The core of the risk lies in the mechanism of failure. These capsules were designed to release the medication slowly over time, mimicking a natural tapering effect that keeps blood levels stable. Because the recalled lot contains only immediate-release (IR) pellets while being labeled as extended-release (ER), a patient taking what they believe is a long-lasting dose will actually receive the full 5 mg of active amphetamine salts immediately upon ingestion. For someone with a sensitive cardiovascular system, this sudden influx can trigger acute stress responses that their body was not prepared to handle gradually. This is particularly concerning for elderly patients who may already have underlying heart conditions or hypertension, as rapid increases in amphetamine levels can elevate blood pressure and heart rate more sharply than intended, potentially leading to arrhythmias or other cardiovascular events.
Furthermore, individuals managing chronic mental health conditions alongside ADHD face a unique set of vulnerabilities. The sudden onset of the full dose can lead to intense side effects such as severe anxiety, agitation, insomnia, or even psychosis-like symptoms that would not typically occur with the gradual release profile they are accustomed to. This abrupt shift in neurochemistry can disrupt daily functioning, making it difficult for patients to work, drive, or care for themselves safely. There is also a significant risk of unintended overdose effects, including tremors, palpitations, and hyperthermia, which require immediate medical attention if severe.
Children and adolescents prescribed this medication are also in the high-risk category. Their developing bodies process drugs differently than adults, and the sudden delivery of the full dose can lead to excessive stimulation, behavioral outbursts, or dangerous physical reactions. Additionally, because this is a controlled substance with potential for misuse, the discrepancy between the label and the contents creates a confusion that could inadvertently encourage improper dosing behaviors if patients suspect the medication is not working as expected. It is crucial that anyone who has been prescribed these specific capsules—particularly those with heart problems, high blood pressure, or a history of mental health issues—treats this recall with immediate seriousness and contacts their healthcare provider before taking any further doses.
How to tell if you have the recalled item
Identifying whether a specific medication bottle is part of this FDA recall requires careful attention to several distinct details on the packaging. Because the issue involves a labeling error where immediate-release capsules were mislabeled as extended-release, simply looking at the box is not enough; you must verify the internal contents against the external label. Start by locating the physical carton or blister pack your medication came in. On the side panel of the box, look for the National Drug Code (NDC) number. For this specific recall, the affected product carries the NDC 0527-0790-37. This code is unique to this particular distribution batch and size. If your bottle does not display this exact NDC sequence, it is not part of this recall event.
Next, check the lot number and expiration date, which are critical for pinpointing the affected units. The recalled items are specifically from Lot # 25285401A. This alphanumeric code is typically printed on the side or bottom of the bottle label, often in a smaller font than the drug name. Alongside this lot number, verify the expiration date, which for this recall is listed as April 2027 (Exp. Date: 04/2027). If your medication has a different lot number or an expiration date other than 04/2027, it was not distributed in the affected batch and is safe from this specific labeling mix-up.
Confirm the drug name and strength as well. The recall pertains to Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Extended-Release Capsules in a 5 mg strength. Ensure the bottle clearly states “Rx Only” and indicates it contains 100 capsules. The distributor listed on the packaging should be Lannett Company, Inc., located in Philadelphia, PA 19136. If any of these details do not match exactly—such as a different manufacturer, a different milligram strength, or a different capsule count—your medication is not included in this recall.
Finally, inspect the actual capsules inside the bottle. The core of this hazard is that the capsules contain only immediate-release (IR) pellets, despite being labeled as extended-release (ER). If you open the bottle and notice that the contents appear to be standard, single-pellet capsules rather than the multi-pellet or specialized ER formulation typically associated with extended-release amphetamine products, this is a significant red flag. However, do not rely solely on appearance alone for confirmation; always cross-reference the NDC, lot number, and expiration date printed on the packaging first. If all the printed identifiers match the recall details above, stop using the medication immediately and follow the remedy instructions provided by Lannett Company or your healthcare provider.
What to do — step by step
If you or a family member have been prescribed this specific formulation of Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate by Lannett Company Inc., your immediate priority must be safety. Because the FDA has classified this recall as Class II, it indicates that use of the product could cause temporary or medically reversible health problems, but the serious risk comes from the unpredictability of the medication's release mechanism. The capsules you possess are labeled as Extended-Release (ER), which means they are designed to slowly release the active ingredients over several hours to maintain steady levels in your bloodstream. However, the investigation revealed that these specific capsules contain only immediate-release (IR) pellets. This is a critical distinction because immediate-release medication dumps its entire dose into your system all at once, rather than spreading it out. To navigate this safely, you should follow these concrete steps without delay.
- Stop taking the medication immediately. Do not take another dose of the recalled capsules. The mismatch between the label and the contents means you are receiving a drug delivery profile that your doctor did not intend. Taking this could lead to an unexpected spike in medication levels, potentially causing side effects like rapid heart rate, anxiety, or high blood pressure, followed by a sudden drop in effectiveness as the drug wears off too quickly.
- Verify your specific stock. Locate your bottle and check the expiration date and lot number. The recall specifically affects 100-count bottles distributed nationwide with Lot Number 25285401A and an expiration date of 04/2027. If your bottle has a different lot number or expiration date, it is not part of this specific recall event. However, if you are unsure or cannot read the label clearly, it is safer to treat it as recalled until confirmed otherwise.
- Contact your healthcare provider right away. This is perhaps the most important step. Because you are stopping a controlled substance prescription, you need medical guidance on how to manage your condition in the interim. Your doctor can assess whether you need a bridge prescription, a dosage adjustment, or a switch to a different manufacturer’s product that uses the correct extended-release technology. Do not attempt to self-manage this transition.
- Arrange for the return of the product. The recall facts provided do not explicitly state the specific remedy, such as whether Lannett Company Inc. is offering direct refunds or replacements. Therefore, you must contact the distributor directly at their Philadelphia, PA address or through your pharmacy’s customer service line to inquire about the return process. Do not throw the medication in the household trash, as this poses a risk of accidental ingestion by children, pets, or others.
- Dispose of the medication safely. If you cannot return the product immediately, follow FDA guidelines for safe disposal. The best option is to take the unused capsules to a pharmacy or law enforcement agency that participates in drug take-back programs. If no take-back location is available, mix the capsules with an unpalatable substance like dirt, cat litter, or coffee grounds in a sealed plastic bag before disposing of them in your household trash. Remove or obscure all personal information on the prescription label to protect your privacy.
By following these steps, you prioritize your health and ensure that this labeling error does not lead to unintended medical consequences. Stay calm, but act promptly to secure proper medical care for your ongoing treatment needs.
Your refund, repair, or replacement options
When you receive official news about a pharmaceutical recall, the immediate question on your mind is often, "What do I do with this product, and will I get my money back?" In this specific instance involving Lannett Company Inc.'s Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Extended-Release Capsules, the situation requires a careful and honest look at the available information. The recall notice provided to us does not explicitly state a standardized remedy such as a direct refund, a repair, or a replacement protocol. This absence of specific instructions in the primary facts can be confusing, but it is important to understand that this does not mean you are left without recourse. It simply means that the standard "return for cash" process you might expect from a consumer electronics recall is not automatically outlined in the public alert.
The reason for this lack of specific remedy details often lies in the nature of prescription drug recalls versus general consumer goods. Unlike a defective toaster where the manufacturer wants the physical unit back to analyze the failure, pharmaceutical companies typically manage recalls through their distribution networks and pharmacies. The primary goal is to remove the product from shelves and patient homes to prevent harm, rather than processing individual financial transactions directly with consumers. Therefore, while a refund or replacement might be part of the broader agreement between Lannett Company Inc. and the retailers or distributors who purchased the affected lots, you, as the end-user, must navigate this through your original point of purchase.
To determine your specific financial options, you should first contact the pharmacy where you filled your prescription. Pharmacies are generally better equipped to handle these logistical complexities than individual patients. They can verify if they have received guidance from Lannett Company Inc. regarding credit memos or stock replacements for their inventory. If you paid out of pocket and cannot reach the pharmacy, your next step should be to check any correspondence you may have received directly from Lannett Company Inc. or the FDA. Often, detailed instructions for Class II recalls, including how to request a refund if applicable, are sent via mail or email to the specific entities that distributed the product, rather than published broadly in the initial recall summary.
In the meantime, do not attempt to sell or donate this medication. The hazard here is a critical labeling mix-up where immediate-release pellets were packaged as extended-release capsules. This means the drug could be absorbed too quickly, potentially leading to dangerous side effects or overdose symptoms. Because the remedy is not stated in our current facts, your safest path is to treat the product as hazardous waste until you speak with a healthcare professional or pharmacist who can guide you on safe disposal and any potential reimbursement through your insurance provider or pharmacy benefit manager.
- Contact your pharmacy first to ask about their specific recall processing procedures.
- Review any direct mailers from Lannett Company Inc. for hidden instructions not found in the general alert.
- Consult your healthcare provider before making any changes to your medication regimen.
What can happen if you ignore it
When a medication is labeled as "extended-release" (ER) but actually contains immediate-release (IR) pellets, the consequences are not merely administrative; they are physiological and potentially dangerous. You might be holding a bottle that says it will deliver your dose slowly over twelve or twenty-four hours, but inside, those capsules are designed to dump the entire amount of medication into your system all at once. Ignoring this mismatch means you are essentially taking a massive, concentrated spike of medication rather than the steady, controlled flow your doctor prescribed.
Dextroamphetamine and amphetamine salts are central nervous system stimulants. When taken in an immediate-release form by mistake, these drugs hit your bloodstream rapidly, leading to a sudden and sharp increase in concentration levels. This is not just about feeling "more awake." It can trigger acute toxicity symptoms that go far beyond typical side effects. You may experience severe tachycardia (a dangerously fast heart rate), hypertension (high blood pressure), and palpitations. For individuals with underlying cardiac conditions, even a single dose of this unintended high concentration can precipitate serious cardiovascular events, including arrhythmias or, in extreme cases, cardiac arrest.
Beyond the immediate physical strain on your heart and blood vessels, the neurological impact is significant. The sudden surge of stimulants can cause intense anxiety, agitation, panic attacks, and tremors. You might feel a sense of impending doom that did not exist before taking the pill. In more severe scenarios, this chemical overload can lead to hyperthermia (dangerously high body temperature), rhabdomyolysis (muscle breakdown that can damage the kidneys), and seizures. These are not theoretical risks; they are well-documented outcomes of stimulant overdose and rapid-onset exposure.
There is also a critical risk regarding your long-term treatment plan. If you experience these acute, uncomfortable side effects, you might stop taking the medication altogether out of fear or physical distress. This abrupt cessation can lead to withdrawal symptoms, including severe fatigue, depression, and cognitive fog, which disrupts your daily life and mental health stability. Conversely, if you continue to take it believing it is working as intended, you are subjecting your body to unpredictable fluctuations in drug levels that make it impossible for your healthcare provider to manage your condition safely. The lack of steady blood levels means your symptoms may return unpredictably, or worse, you may suffer from toxicity without realizing the cause.
The FDA has classified this recall as Class II, which indicates that use of the product could cause temporary medical problems or pose a threat of a serious nature. While no specific injuries have been reported in the current data for this lot, the potential for harm is real and immediate. Continuing to use these capsules means gambling with your cardiovascular health and neurological stability. It is not worth the risk of waiting for a problem to manifest when you can simply stop taking them now.
- Cardiovascular Stress: Rapid heart rate, high blood pressure, and potential heart rhythm disturbances.
- Neurological Overload: Severe anxiety, tremors, agitation, and risk of seizures.
- Systemic Toxicity: Hyperthermia and potential kidney damage from muscle breakdown.
- Treatment Disruption: Unpredictable symptom control and potential withdrawal effects.